Biom'Up S.A. announced the publication of scientific and clinical data with the company’s product HEMOBLAST Bellows, a hemostatic product to control bleeding in a broad range of both traditional and laparoscopic surgical procedures in the January edition of the Journal of Cardiac Surgery. The Journal of Cardiac Surgery is a peer-reviewed, international publication devoted to contemporary surgical treatment of cardiac diseases. The clinical data, published in open access in the article entitled “Evaluation of the safety and efficacy of a new hemostatic powder using a quantitative surface bleeding severity scale”, clearly demonstrates the outstanding superiority of HEMOBLAST Bellows in terms of effectiveness for patients and surgeons under the usage prerequisites versus a control agent. In comparison to absorbable gelatin sponge and thrombin, HEMOBLAST Bellows achieved hemostasis in 71.1% of patients within three minutes (45.8% in the control arm) and in 93.1% of patients within six minutes (73.5% in the control arm). No signs or symptoms of postoperative bleedings were observed with HEMOBLAST Bellows. HEMOBLAST Bellows met all primary and secondary endpoints with high statistical significance prior to completion of the clinical trial at the scheduled interim analysis. The results were assessed using the only quantitative bleeding severity scale (SPOT GRADE™ Surface Bleeding Severity Scale, SBSS) clinically validated by the FDA and another major Biom’up innovation.